The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series

Nasikarn Angkasekwinai[1,*], Suvimol Niyomnaitham[2,3,*], Jaturong Sewatanon[4], Supaporn Phumiamorn[5], Kasama Sukapirom[6,7], Sansnee Senawong[8], Surakameth Mahasirimongkol[5], Zheng Quan Toh[9,10], Pinklow Umrod[8], Thitiporn Somporn[5], Supaporn Chumpol[5], Kanokphon Ritthitham[5], Yuparat Jantraphakorn[12], Kanjana Srisutthisamphan[12], Kulkanya Chokephaibulkit[3,11]

[1]Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[2]Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[3]Siriraj Institute of Clinical Research (SICRES), Mahidol University, Thailand

[4]Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[5]Department of Medical Sciences, Ministry of Public Health, Thailand

[6]Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[7]Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, Thailand

[8]Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[9]Murdoch Children's Research Institute, Parkville, Victoria, Australia

[10]Department of Pediatrics, The University of Melbourne, Parkville, Victoria, Australia

[11]Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[12]Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.

Corresponding author:

Kulkanya Chokephaibulkit, MD

Professor of Pediatrics,

Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University

Siriraj Institute of Clinical Research (SICRES)

2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

Tel: (+66) 2-4141899; Fax: (+66) 2-4128243

E-mail: kulkanya.cho@mahidol.ac.th

*Nasikarn Angkasekwinai and Suvimol Niyomnaitham equally contributed to the research work.

Abstract word count: 350

Manuscript Text word count: 2959

KEY POINTS

Question: Which COVID-19 booster vaccine is most immunogenic following 2-dose CoronaVac or ChAdOx1 primary series?

Findings: This prospective cohort study found that BNT162b2 given half or standard dosage as a booster (3rd dose) vaccination induced the highest humoral responses against the original SARS-CoV-2 Wuhan strain, and the SARS-CoV-2 variants (Delta, Beta, and Omicron). Boosting with inactivated vaccine (BBIBP-CorV) induced poor humoral and cellular immune responses.

Meaning: Heterologous boosting with half or standard dosage of BNT162b2 following CoronaVac or ChAdOx1 primary series is safe and highly immunogenic, and likely to confer protection against the SARS-CoV-2 variants.

Abstract

Importance: The immunogenicity of COVID-19 booster vaccine following inactivated or chimpanzee adenoviral vector COVID-19 vaccination is unclear.

Objectives: To determine the reactogenicity and immunogenicity of different booster vaccine following CoronaVac (by Sinovac) or ChAdOx1 (by AstraZeneca) primary series vaccination.

Design: Prospective, non-randomized, open-labeled cohort study

Setting: A single center, tertiary care university-based hospital in Bangkok.

Participants: Healthy adults who received a 2-dose homologous primary series of either CoronaVac or ChAdOx1 8-12 weeks earlier.

Intervention: One of the four booster vaccines: BBIBP-CorV (by Sinopharm), ChAdOx1, 30µg-BNT162b2 (by Pfizer) or 15µg-BNT162b2 vaccine**s.**

Main Outcomes and Measures: Self-reported adverse events (AEs) for 7 days following vaccination were collected by electronic diary system. The immunogenicity was determined by IgG against receptor binding domain (RBD) of the SARS-CoV-2 spike protein, 50% plaque reduction neutralization test ($PRNT_{50}$) against Delta and Beta variants, 50% pseudovirus neutralizing antibody ($PVNT_{50}$) against Delta and Omicron variants, and whole blood interferon gamma (IFN-$\square$) releasing assay.

Results: Among the 352 participants (179 in CoronaVac- and and 173 in ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range: 31-47) years.

The AEs for all booster vaccines were mild to moderate. Two weeks post-booster, 30µg-BNT162b2 induced the highest anti-RBD IgG concentration in the CoronaVac- and ChAdOx1-prime groups (5152 and 2364 BAU/mL), followed by 15µg-BNT162b2 (3981 and 1962

BAU/mL), ChAdOx1 (1358 and 246 BAU/mL), and BBIBP-CorV (154 and 128 BAU/mL), respectively. The $PRNT_{50}$ against the Delta variant were also highest with 30µg-BNT162b2 (411 and 470) and 15µg-BNT162b2 (499 and 358); followed by ChAdOx1 (271 and 69), and BBIBP-CorV (61.3 and 49) for CoronaVac and ChAdOx1-prime, respectively. Similar trend was observed for $PRNT_{50}$ against the Beta variant. The $PVNT_{50}$ against the Omicron variant was highest with 30µg-BNT162b2 (543 and 521) followed by 15µg-BNT162b2 (551 and 232) for CoronaVac- and ChAdOx1-prime, respectively. BNT162b2 vaccine also induced the highest IFN-□ response in both CoronaVac- and ChAdOx1-prime groups.

Conclusions and Relevance: Heterologous boosting vaccination with BNT162b2 following CoronaVac or ChAdOx1 primary series is the most immunogenic against SARS-CoV-2 variants. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

Trial Registration: Thaichinicaltrials.org (TCTR20210719006).

Introduction

Both CoronaVac (an inactivated whole-virion SARS-CoV-2 vaccine, Sinovac Life Science) and ChAdOx1 (a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein, Oxford, AstraZeneca) are safe and effective vaccines against symptomatic COVID-19 caused by the ancestral Wuhan strain, and to a lower extent against the Delta variant.[1–7] These two vaccines are widely used vaccines globally, particularly in low- and middle-income countries.[8]

Breakthrough infections following COVID-19 vaccination, which are likely due to a combination of waning immunity and the emergence of SARS-CoV-2 variants, have led to the need for booster vaccination.[9–13] While the antibody threshold of protection has not been identified, higher antibody levels are likely to be associated with greater protection.[7] Cell mediated immune responses generated following vaccination also plays an important role in protection against SARS-CoV-2.

Several studies have demonstrated improved humoral responses with heterologous COVID-19 prime-boost vaccination, primarily on ChAdOx1 and mRNA vaccines.[14–18] However, other combinations of prime-boost COVID-19 vaccination involving inactivated COVID-19 vaccines have not been evaluated. Furthermore, the persistence of immunity following a booster (3rd) dose of COVID-19 vaccine is unknown. A recent study of reduced dosage of mRNA-1273 vaccine as a booster was found to be highly immunogenic, suggesting that a lower dosage vaccine may be equally immunogenic as a standard dosage, particularly for mRNA vaccines.[19]

In this study, we examined the safety and immunogenicity of four booster vaccinationsat 2 weeks and up to 16-20 weeks in healthy adults who previously received a 2-dose primary series of CoronaVac or ChAdOx1 vaccine 8-12 weeks earlier.

Material and Methods

Study design and participants

This single-center prospective, non-randomized, open-labeled cohort study enrolled 352 healthy adults, aged 18 years or older at Siriraj Hospital, a university-based referral center in Bangkok, Thailand, from July to September 2021. The eligible participants were those who have received either 2 doses of CoronaVac (4 weeks apart) (CoronaVac-prime) or ChAdOx1 (8-10 weeks apart)(ChAdOx1-prime) primary series vaccination 8-12 weeks prior to recruitment. The exclusion criteria were history of SARS-CoV-2 infection; prior received prophylactic or investigational treatment against COVID-19 within 90 days; had an unstable underlying disease; history of vaccine anaphylaxis; being pregnant; immunocompromised or currently receiving immunosuppressive agents. Written informed consent was obtained from all study participants. The study protocol was approved by the Siriraj Institutional Review Board (COA no. Si 537/2021). The study was registered in thaichinicaltrials.org (TCTR20210719006).

Study Procedures

Eligible participants were openly assigned to receive one of the four intramuscular booster vaccinations: BBIBP-CorV (Sinopharm), ChAdOx1 (AstraZeneca), full dose [30 µg] or half dose [15 µg] BNT162b2 (Pfizer). The participants were observed for at least 30 min following vaccination for any immediate adverse events (AE) and were instructed to record self-

assessment signs or symptoms in an electronic diary (eDiary) for seven days after vaccination. An AE were defined as described in the previous study.[7]

Blood samples were collected at baseline (pre-booster), two weeks, and 16-20 weeks after booster vaccination to determine the SARS-CoV-2 IgG antibody levels. A subset of samples at two weeks and 16-20 weeks post-booster were tested for neutralizing antibodies against the SARS-CoV-2 Delta and Beta variants using the 50% plaque reduction neutralization test ($PRNT_{50}$) and against Delta and Omicron variants using the pseudovirus neutralization test (PVNT). The groups that received BBIPB-CorV as booster or ChAdOx1 as priming and booster (3-dose ChAdOx1)-boost were not followed up for the 16-20 weeks analysis; the participants have received additional booster vaccination outside of this study. Cellular immunity was measured at baseline using the QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA). Participants with a negative IGRA response at baseline were tested again at two weeks post-booster.

Laboratory Assays

Chemiluminescent microparticle assay (CMIA) for anti-SARS-CoV-2 RBD IgG

The anti-RBD IgG was measured by CMIA using the SARS-CoV-2 IgG II Quant (Abbott, List No. 06S60) on the ARCHITECT i System as described in previous study.[7] Samples with a value >11,360 BAU/mL were reported as 11,360 BAU/mL.

50% plaque reduction neutralization test ($PRNT_{50}$)

The standard live virus 50% plaque reduction neutralization test ($PRNT_{50}$) against Delta variant (B.1.617.2) and Beta variant (B.1.351) were performed as described in the previous

study.[7] The $PRNT_{50}$ titer is defined as the the highest test serum dilution for which the virus infectivity is reduced by 50% when compared with the average plaque counts of the virus control (no serum). The $PRNT_{50}$ titer of 5 was used for all samples that were below the detectable level (< 1:10).

Pseudovirus neutralization assay (PVNT)

Codon-optimized gene encoding the spike of Omicron (B.1.1.529/ BA.1) and Delta (B.1.617.2) were generated by gene synthesis (Genscript) and cloned into the pCAGGS expressing plasmid by In-Fusion assembly (Clontech). Pseudovirus was generated and concentrated as previously described.[20] Pseudotype-based neutralization assays were carried out as described previously.[20] The 50% neutralizing antibody titer ($PVNT_{50}$) was calculated by interpolating the point at which infectivity was reduced to 50% of the value for the control samples (no serum).

QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA)

SARS-CoV-2 specific T cell responses were assessed by whole blood IGRA using QIAGEN's proprietary mixes of SARS-CoV-2 S protein designed for CD4+ T cell (Ag1), CD8+ T cells (Ag2) according to the manufacturer's instruction. Interferon-gamma (IFN-□) concentration was measured with an automated QuantiFERON SARS-CoV-2 ELISA instrument and reported in International Units per mL (IU/mL).[21–22] The cut-off for positivity was determined as the level above the mean plus three standard deviations of the negative control. The cut-offs for Ag1 (>0.12 IU/mL) and Ag2 (>0.17 IU/mL) were determined based on 61

SARS-CoV-2 negative control samples. A positive response to either of the two peptides pools was considered positive.

Statistical Analysis

The AEs endpoints were presented as frequencies and Chi-square test was used to test for statistical difference. The anti-SARS-CoV-2 RBD IgG concentration and neutralization antibodies were reported as geometric mean concentration (GMC) and geometric mean titers (GMT) with 95% confidence interval (CI), respectively. Anti-RBD IgG GMC and $PRNT_{50}$ GMTs at two weeks after the primary series (post-primary series) from our previous study was used for comparison[7]: the anti-RBD IgG GMC for CoronaVac and ChAdOx1 was 164.4 BAU/mL and 278.5 BAU/mL, respecitively and the $PRNT_{50}$ GMT was 21.2 and 69.7 for Delta variant and 10.2 and 43.5 for Beta variant, respectively.[7] The geometric mean ratio (GMR) with 95% CI was analyzed between the post-boosting levels or titers and post-primary series levels or titers references. Paired t test, unpaired t test, and analysis of variance (ANOVA) were used to compare GMC and GMT within group, between groups, and across groups using GraphPad Prism 9 version 9.2.0 (283) (GraphPad Software, CA, USA), respectively. Other statistical analyses were conducted using STATA version 17 (Stata Corp, LP, College Station, TX, USA).

Results

Among 352 participants enrolled (179 and 173 participants in CoronaVac- and ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range, IQR: 31-47) years. The demographic of the study participants receiving different booster vaccine was shown in Table 1.

Adverse events (AEs)

Among the CoronaVac-prime groups, the frequency of overall AEs was the highest after boosting with ChAdOx1 (98%), followed by 30µg-BNT162b2 (92%), 15µg-BNT162b2 (80%), and BBIBP-CorV (70%); whereas in ChAdOx1-prime group, the highest rate of overall AEs was after boosting with 30µg-BNT162b2 (98%), followed by 15µg-BNT162b2 (88%), ChAdOx1 (72%), and BBIBP-CorV (61%) (Fig. 1, Supplementary Table 1). Systemic AEs were in the same trend as local AEs (Fig. 1, Supplementary Table 1). All AEs were mild (grade 1) to moderate (grade 2) in severity and recovered within 2-3 days. No serious AEs was found in this study.

Anti-SARS-CoV-2 RBD IgG responses

At baseline (8-12 weeks post-primary series), 175/179 (97.8%) participants in CoronaVac-prime and 172/173 (99.4%) in ChAdOx1-prime remained seropositive. The anti-RBD IgG GMCs at baseline were lower in the CoronaVac-prime groups than in the ChAdOx1-prime group (36.31 vs. 98.27 BAU/mL) (Fig. 2A-B). For the CoronaVac-prime groups, the anti-RBD IgG GMC post-booster in the 30µg-BNT162b2 group (5,152 BAU/mL) was significantly higher than other booster vaccine groups: 15µg-BNT162b2 (3,981 BAU/mL), ChAdOx1 (1,358 BAU/mL), and BBIBP-CorV (154 BAU/mL) (Fig. 2A). The GMR between post-boost and post-primary series of CoronaVac were 0.94, 8.26, 31.34, and 24.22 for BBIBP-CorV, ChAdOx1, 30µg-BNT162b2 and 15µg-BNT162b2, respectively (Supplementary Table 2).

For the ChAdOx1-prime group, the anti-RBG IgG GMC post-booster was significantly higher in participants who received 30µg-BNT162b2 (2,364 BAU/mL) or 15µg-BNT162b2

(1,962 BAU/mL) compared to those who received ChAdOx1 (246.4 BAU/mL), and BBIBP-CorV (128.1 BAU/mL) (Fig. 2B). The GMR between post-boost and post-primary series of ChAdOx1 were 0.46, 0.88, 8.49, and 7.04 for BBIBP-CorV, ChAdOx1, 30μg-BNT162b2 and 15μg-BNT162b2, respectively (Supplementary Table 2). The post-boost GMC levels in ChAdOx1-prime were generally lower than that in the CoronaVac-prime group for all booster vaccines (Fig. 2C).

Among the participants who received BNT162b2 as booster or received CoronaVac as priming and ChAdOx1 as booster that were followed up at 16-20 weeks, there was a significant decline in anti-RBD IgG GMC (4.7 to 7.5-fold) from 2-weeks post booster vaccination (Table 1).

Neutralizing antibody responses against the SARS-CoV-2 variants

For both the CoronaVac-prime and ChAdOx1-prime groups, the $PRNT_{50}$ GMT against the Delta (Fig. 3A) and Beta (Fig. 3B) variant were significantly higher among those who received a booster dose of BNT162b2 (30μg or 15μg) compared to those who received ChAdOx1 or BBIBP-CorV. There was no statistical difference in $PRNT_{50}$ between boosting with 30μg and 15μg- BNT162b2 regardless of the primary series vaccine and the type of variants. However, the $PRNT_{50}$ against the Beta variant was in general around 1.5-fold lower than the Delta variants for both CoronaVac-prime and ChAdOx1-prime groups (Fig. 3C). The GMRs of the $PRNT_{50}$ between post-boost and post-primary series were highest among the participants who received BNT162b2 boosting vaccination in both CoronaVac-prime and ChAdOx1-prime groups (Table 2). The SARS-CoV-2 RBD IgG levels and the neutralizing titers against Delta variant (Supplementary Fig. S1: A and B) or Beta variant (Supplementary Fig. S1: C and D) were strongly correlated (r = 0.49-0.89).

Using the PVNT assay, the $PVNT_{50}$ GMT against Omicron was 2- to 37-folds lower than the that against Delta (Fig. 3D and Table 2). Among the CoronaVac-prime groups, 15µg and 30µg-BNT162b2 booster induced similar $PVNT_{50}$ against Omicron, whereas in the ChAdOx1-prime groups, the group that received 15µg-BNT162b2 induced significantly lower $PVNT_{50}$ against Omicron compared to the 30µg-BNT162b2 group. Notably, the groups that received ChAdOx1 booster had significantly lower $PVNT_{50}$ against Delta and Omicron variants than the groups that received 15µg- or 30 µg BNT162b2. Between the groups that received ChAdOx1 booster, CoronaVac-prime-ChAdOx1-boost had significantly higher $PVNT_{50}$ against Delta and Omicron variants than the ChAdOx1-prime-ChAdOx1-boost group (Fig 3D and Table 2).

At 16-20 weeks after boosting, there was a significant decline in $PVNT_{50}$ against Delta and Omicron from two weeks post booster in both the CoronaVac-prime and ChAdOx1-prime groups (Table 2). No significant difference in $PVNT_{50}$ against Delta and Omicron was observed between the CoronaVac-prime and ChAdOx1-prime groups (Table 2). However, a more significant drop in $PVNT_{50}$ against Omicron (4.5 to 122 folds) was observed compared to the Delta variant (4 to 9-fold) (Table 2 and Supplementary Fig. S3).

QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA)

At baseline, a higher proportion of 62/173 (35.8%) of participants in ChAdOx1-prime group and 45/179 (25%) of CoronaVac-prime group had positive IGRA (P=0.029). Among those with negative IGRA at baseline, IGRA conversion was the highest after a booster dose of 30µg-BNT162b2, followed by 15µg-BNT162b2, ChAdOx1, and BBIBP-CorV (Supplementary Table 2). None of the study participants who were IGRA-negative at baseline in the ChAdOx1-prime

group had a positive IGRA response following boosting with BBIBP-CorV or ChAdOx1 (Supplementary Table 2 and Supplementary Fig. S2).

Discussion

In this study, BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced dosage) given as booster dose to individuals who previously received either CoronaVac or ChAdOx1 primary series were found to be safe and well tolerated. BNT162b2 given as a booster induced the highest humoral and cellular immune responses compared to BBIBP-CorV or ChAdOx1. Furthermore, both 15µg and 30µg-BNT162b2 induced similar humoral responses against the SARS-CoV-2 Wuhan strain and variants for both CoronaVac- and ChAdOx1- prime groups, except for some differences in the neutralising antibody titres against the Omicron variant in the ChAdOx1-prime group. Notably, higher humoral response was observed in the CoronaVac-prime group following the booster dose compared to the ChAdOx1-prime group, despite lower circulating antibodies at baseline, suggesting better immune memory response generated by CoronaVac. We also found that the SARS-CoV-2 specific antibodies, particularly against the Omicron decline rapidly by 16-20 weeks following the booster dose. This has important implications on the efficacy of these booster vaccines against infection and severe disease caused by the highly transmissible Omicron SARS-CoV-2 variant beyond 16-20 weeks.

Heterologous boosting vaccination in our study were safe, and the AEs rates observed in this study were in line with those reported in COVID-19 vaccine primary series and booster studies.[19,23] Heterologous boosting regimen were also found to be more immunogenic than homologous ChAdOx1 boosting regimen or homologous inactivated vaccines regimen (CoronaVac prime-BBIBP-CorV boost) in our study, which was consistent witha recent study.[24]

However, heterologous boosting with BBIBP-CorV vaccine was poorly immunogenic, which was in line with previous studies, including a study that revealed poor immunogenicity of heterologous ChAdOx1 prime-VLA2001 (inactivated vaccine by Valvena) boost.[24] Our findings suggest that inactivated whole virus vaccine may not be effective booster vaccine.

The SARS-CoV-2 Omicron variant, recently identified in November 2021 has been reported to evade immunity induced from past infection or two vaccine doses.[25-27] Our results suggest that a third dose of BNT162b2 is able to overcome this immune evasion through the induction of neutralising antibodies. A recent study also reported high antibodies against Omicron following a third dose of mRNA vaccines (mRNA-1273 or BNT162b2).[29] Heterologous boost with ChAdOx1 was immunogenic in CoronaVac-prime participants but was poorly immunogenic in ChAdOx1-prime recipeints. Taken together, these data support the use of BNT162b2 as a booster regardless of the primary series against the Delta and Omicron variants that are widely circulating globally. Consequently, ChAdOx1 may also be use as a booster for CoronaVac-prime participants.

The persistence of immunity following COVID-19 booster is unknown. Our findings suggest rapid waning humoral immunity against the SARS-CoV-2 variants, particularly for Omicron. This has significant concerns on the protection against Omicron after 5 months of receiving the booster vaccination. A fourth booster dose study has been studied in high risk groups[30] and also is currently under investigation in Israel.[31] However, it is important to note that the antibody threshold of protection against infection and severe disease has not been identified, and immune memory cells which are thought to be important for long-term protection was not measured in our study.

Virus-specific memory T cells are important for protection against SARS-CoV-2, particularly against severe disease. Only a third of ChAdOx1-prime and a quarter of CoronaVac-prime participants in our study remained positive for IGRA as a marker for T cell response at 8-12 weeks post primary series. Previous studies evaluating 2-dose ChAdOx1 primary series have reported the generation of robust T cell response following the first dose, with no significant increase in T cell responses following the second dose,[32–33] and following a homologous ChAdOx1 booster.[24] The discrepancy in T cell responses from our study could be due to waning immunity, population differences and the different assays used to measure IFN-□ response (Quantiferon vs. IFN-□ ELISPOT). On the other hand, the study of 2-dose CoronaVac primary series revealed poor inducer of T-cell response.[34] It is important to note that inactivated vaccine (i.e. BBIBP-CorV) may have other antigens (i.e., M or N proteins) that induce T cell responses,[35] whereas in our study, we only examined T cell responses to S protein, and thus may have underestimated the cellular responses. The low T cell boosting responses following homologous boosting regimen of ChAdOx1 is in line with the low neutralizing antibody boosting responses observed in this study. This could be explained by the anti-vector interference, possibly due to a short interval (8-12 weeks) between the third and second dose. Further studies are needed to monitor the efficacy of homologous ChAdOx1 prime-prime-boost schedules or when BBIBP-CorV is used as a booster.

Our finding that half-dose BNT162b2 was equally immunogenic as the standard dosage, but with less reactogenicity, suggesting that less amount of antigen may be sufficient for boosting immune responses against SARS-CoV-2. This finding is in concordance with previous study on mRNA1273 vaccine where half dose of the mRNA1273 (50 µg) was able to induce significantly higher neutralizing antibodies than the level induced after primary series and

against the SARS-CoV-2 variants of concerns.[19] A lower mRNA vaccine dose may be considered for COVID-19 booster vaccination, given that the limited vaccine supply globally.

There are some limitations in this study. First, our study was conducted in a non-randomized open label manner which was due to the availability of each vaccine at a different timing may lead to selection bias. Second, our sample size is small, particularly those who received BBIBP-CorV as booster; therefore, the data need to interpret with caution. Third, the participants in this study were healthy adults, and may not be generalized to other populations such as immunocompromised individuals. Lastly, how our findings translate to disease protection warrant further investigation.

Conclusion

A booster dose of BNT162b2 given to individuals previously vaccinated with CoronaVac or ChAdOx1 is the most immunogenic and induced high cross protective antibodies against Delta, Beta, and Omicron variants. The rapid decline of antibodies after 16-20 weeks of receiving the booster warrants further investigation into the efficacy of the booster dose, and other COVID-19 vaccines and heterologous regimens in protection against SARS-CoV-2. Our study findings have important implications on the choice of booster dose for countries that have introduced CoronaVac or ChAdOx1 as primary series to date. Our study also suggests that reduced dosage of BNT162b2 may be used as a booster dose that may be highly relevant for countries with limited vaccine supply particularly if CoronaVac was used in the primary series.

Acknowledgement

The authors gratefully acknowledge the Siriraj Institute of Clinical Research (SICRES) team, Abbott Laboratories Ltd. for technical supports and all health care workers who took part and enabled this study to be possible. We are also grateful to Professors Kim Mulholland and Paul Licciardi, Murdoch Children's Research Institute, who provided review and critical comments to improve the study and the manuscript.

Conflict of Interest Declaration

All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drugs, devices, or materials described in this report.

Funding Disclosure

This study was supported by the National Research Council of Thailand. The Abbott Laboratories Ltd. partially supported the reagents for the anti-SARS-CoV-2 RBD IgG in this study. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

References

1.   Tanriover M, Doğanay H, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet.* 2021;398(10296)**:**213–222.

2.   Voysey M, Clemens S, Madhi S, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99–111.

3.   Jara A, Undurraga E, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med*. 2021;385(10):875–884.

4.   Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585–594.

5.   Li X, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. *Emerg Microbes Infect*. 2021;10(1):1751–1759.

6.   Mallapaty S. China's COVID vaccines have been crucial — now immunity is waning. October 14, 2021. Accessed October 21, 2021. https://www.nature.com/articles/d41586-021-02796-w

7.   Angkasekwinai N, Sewatanon J, Niyomnaitham S, et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. *medRxiv*. Preprint published online October 7, 2021. doi: 10.1101/2021.10.03.21264451

8. Mallapaty S, Callaway E, Kozlov M, et al. How COVID vaccines shaped 2021 in eight powerful charts. December 16, 2021. Accessed December 27, 2021. https://www.nature.com/articles/d41586-021-03686-x

9.   Khoury D, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205–1211.

10.   Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. *Lancet Reg Health Eur*. 2021;10:100208.

11.   Lopez Bernal J, Andrews N, Gower C et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. 2021; n1088.

12.   AlQahtani M, Bhattacharyya S, Alawadi A, et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. *Res Sq*. Preprint published online August 24, 2021. doi: 10.21203/rs.3.rs-828021/v1

13.   Dejnirattisai W, Shaw R, Supasa P, Liu C, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet*. Published online December 20, 2021. doi: 10.1016/S0140-6736(21)02844-0

14.   Borobia A, Carcas A, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021;398(10295):121–130.

15.   Barros-Martins J, Hammerschmidt S, Cossmann A, et al. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *medRxiv*. Preprint published online June 3, 2021. doi: 10.1101/2021.06.01.21258172

16.   Groß R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. *medRxiv*. Preprint published online July 15, 2021. doi: 10.1101/2021.05.30.21257971

17.   Yorsaeng R, Vichaiwattana P, Klinfueng S, et al. Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). *medRxiv*. Preprint published online September 3, 2021. doi: 10.1101/2021.09.01.21262955

18.   Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *Lancet Reg Health Eur*. 2021;11:100249.

19.   Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med*. 2021;27(11):2025–2031.

20.   Koonpaew S, Kaewborisuth C, Srisutthisamphan K, et al. A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model. *Vaccines*. 2021;9(8):850.

21.   Murugesan K, Jagannathan P, Pham T, et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. *Clin Infect Dis*. 2020;73(9):e3130–e3132.

22.   Martínez-Gallo M, Esperalba J, Pujol-Borrell R, et al. Commercialized kits to assess T-cell responses against SARS-COV-2 s peptides. A pilot study in health care workers. *Med Clín (Barc)*. Published online September 25,2021. doi: 10.1016/j.medcli.2021.09.013

23.   Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *Lancet Infect Dis*. 2021;21(7):939–949.

24.   Munro A, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet*. Published online December 2, 2021. doi: 10.1016/s0140-6736(21)02717-3

25.   Carreño J, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature*. Published online December 31, 2021. doi: 10.1038/d41586-021-03846-z

26.   Ferguson N, Ghani A, Cori A, et al. Report 49: Growth, population distribution and immune escape of Omicron in England. December 16, 2021. Accessed January 9, 2022. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/

27.   Yang W, Shaman J. SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant. *medRxiv*. Preprint published online December 21, 2021. doi: 10.1101/2021.12.19.21268073

28.   Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. *NEJM*. Published online December 29, 2021. doi: 10.1056/NEJMc2119358

29.   Garcia-Beltran W, St. Denis K, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *medRxiv*. Preprint published online January 6, 2021. doi: 10.1101/2021.12.14.21267755

30.   Kamar N, Abravanel F, Marion O, et al. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant. *JAMA Netw Open*. 2021;4(11):e2136030.

31.   Burki T. Fourth dose of COVID-19 vaccines in Israel. *Lancet Respir Med*. Published online January 11, 2022. doi: 10.1016/S2213-2600(22)00010-8

32.   Folegatti P, Ewer K, Aley P, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467–478.

33.   Ramasamy M, Minassian A, Ewer K, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet*. 2020;396(10267):1979–1993.

34.   Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. 2021;21(2):181-192.

35.   Vályi-Nagy I, Matula Z, Gönczi M et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. *Geroscience*. 2021;43(5):2321–2331.

Figure Legend

Figure 1. Adverse events following four different booster vaccinations. The stacked bars showed the percentage of participants who reported mild and moderate adverse events after the booster vaccinations in the subjects who had received 2-dose CoronaVac-primary series (A) and ChAdOx1-primary series (B) vaccination. Chi-square was used for statistical analyses.

Figure 2. Quantitation of SARS-CoV-2 RBD IgG 2 weeks after booster vaccination. The scatter dot plot demonstrates the anti-SARS-CoV-2 RBD IgG concentration before and 2 weeks after different booster vaccination in participants who had received 2-doses CoronaVac primary series **(A)** or ChAdOx1-primary series **(B)** 8-12 weeks prior. **(C)**. Comparison of SARS-CoV-2 RBD IgG levels at 2 weeks after booster vaccination between participants who received CoronaVac primary series (blue) or ChAdOx1 primary series (red) Error bars represent geometric mean and 95% confidence interval. The number of tested samples were indicated for each type for booster vaccine. The upper dotted line represents the geometric mean concentration (GMC) of SARS-CoV-2 RBD IgG at 2 weeks after the second dose of the 2-dose primary series of the respective vaccine. The lower dotted line represents the cut-off level for seropositivity.

Figure 3. Plaque reduction neutralization test (PRNT$_{50}$) titers for SARS-CoV-2 Delta and Beta variants and pseudovirus neutralizing antibody (PVNT$_{50}$) for Delta and Omicron after different booster vaccines. Scatter dot plots demonstrate PRNT$_{50}$ titer against the **(A)** Delta or **(B)** Beta strain at 2 weeks after different booster vaccines in the study subjects who had completed two doses of Coronavac or ChAdOx1 for 8-12 weeks. **(C)** Comparison of PRNT$_{50}$ between SARS-CoV-2 Delta (green) and Beta (pink) variants 2 weeks after booster vaccination **(D)** Comparison of PVNT$_{50}$ between SARS-CoV-2 Delta (green) and Omicron (purple) variants 2 weeks after booster vaccination Error bars represent geometric mean titer (GMT) and 95% confidence interval (CI). The upper dotted line represents the geometric mean values of anti-SARS-CoV-2 RBD IgG at 2 weeks after the second dose of the 2-dose primary series of their respective vaccine[7]; and the lower dot line represents the cut-off level for seropositivity.

Supplementary Figure S1. Correlation between the level of anti-SARS-CoV-2 RBD IgG and plaque reduction neutralization test (PRNT$_{50}$) titers for the SARS-CoV-2 Delta and Beta variants. Dot plots show the correlation between the level of anti-SARS-CoV-2 RBD IgG and PRNT$_{50}$ titer against the Delta participants who had completed two doses of CoronaVac (A) or ChAdOx1 (B) or Beta variant in participants who had completed two doses of CoronaVac (C) or ChAdOx1 (D) at 2 weeks after booster with BBIBP-CorV (green), ChAdOX1 (red), 30 µg BNT162b2 (orange) and 15 µg BNT162b2 (yellow). Pearson's correlation coefficient (r) with *p* value for each booster vaccine indicated.

Supplementary Figure S2. Cellular immune responses by interferon-gamma (IFNγ) releasing assay (IGRA). (A) Scatter dot plots show the level of IFNγ production in the blood after being stimulated with either Ag1 or Ag2 at 8-12 weeks after two doses of CoronaVac or ChAdOx1 (before booster vaccination). Aligned dot plots show the level of IFNγ production in the blood after being stimulated with either **(B)** Ag1 or **(C)** Ag2 in samples collected before (teal) and 2 weeks after (pink) booster with BBIBP-CorV, ChAdOX1, 30 µg BNT162b2 and 15 µg BNT162b2. Median and interquartile range (IQR) of each group are indicated. IU/mL: international units per mL.

Supplementary Figure S3. Neutralizing antibody titers against delta and omicron variants at 2 and 16-20 weeks after booster dose. Aligned dot plots show the titers of the neutralizing antibody titers at 2 and 16-20 weeks after the booster dose against the **(A)** Delta and **(B)** Omicron variants as determined by the pseudovirus neutralization assay. The geometric mean titer of each group was indicated, and paired t-test was used.

Table 1: Baseline characteristics of participants

Type of booster vaccinations					
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value
Age (years), median (IQR)	31 (27, 41.5)	36.6 (29.5, 44)	32 (28, 41.8)	40 (31.5, 45.3)	0.018
Female, n (%)	12 (85.7)	51 (78.5)	40 (80.0)	33 (66.0)	0.249
BMI (kg/m^2), median (IQR)	25.2 (21.1, 31.6)	23.4 (20.9, 27.1)	22.1 (19.5, 25.5)	23.9 (20.9, 26.0)	0.325
ChAdOx1-prime (n=173)					
	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value
Age (years), median (IQR)	51 (42, 59)	45.5 (36, 57)	34 (30, 43)	41.5 (34, 49.5)	0.001
Female, n (%)	21 (91.3)	47 (94.0)	37 (74.0)	44 (88.0)	0.001
BMI (kg/m^2), median (IQR)	24.8 (22.4, 27.6)	23.8 (21.3, 26.7)	21.4 (19.3, 24.7)	23.3 (20.4, 26.5)	0.001

Table 2: 50% plaque reduction neutralization (PRNT$_{50}$) and 50% pseudovirus neutralization (PVNT$_{50}$) geometric mean antibody titers (GMT) against SARS-CoV-2 variants.

	Type of booster vaccinations				
CoronaVac-prime (n=104)	BBIBP-CorV	ChAdOx1	30 µg BNT162b2	15 µg BNT162b2	*p*-value
	n=14	n=30	n=30	n=30	
PRNT$_{50}$ at 2 weeks after boosting					
GMT (95% CI) against Delta variant	61.3	271.2	411.1	499.12	<0.0001
	(35.07, 107.02)	(222.54, 330.49)	(311.71, 542.16)	(418.54, 595.21)	
GMR (95% CI) between post-boosting and post-primary series* against Delta variant	2.89	12.79	19.39	23.54	<0.0001
	(1.52, 5.50)	(9.06, 18.06)	(13.04, 28.84)	(16.89, 32.82)	
GMT (95% CI) against Beta variant	37.2	170.5	306.7	322.8	<0.0001
	(18.00, 76.91)	(124.65, 233.13)	(221.44, 424.71)	(239.34, 435.25)	
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	3.65	16.72	30.07	31.65	<0.0001
	(1.65, 8.08)	(11.11, 25.15)	(19.79, 45.69)	(21.27, 47.09)	
PVNT$_{50}$ at 2 weeks after boosting		n=20	n=20	n=20	
GMT (95% CI) against Delta variant	NA	586.65	1,584.8	1,512.7	0.0012
		(437.72, 786.25)	(1,192.1, 2,106.9)	(1,061.6, 2,155.5)	
GMT (95% CI) against Omicron variant	NA	169.59	542.6	551.29	0.001
		(111.80, 257.26)	(317.52, 927.25)	(384.25, 790.96)	
PVNT$_{50}$ at 16-20 weeks after boosting		n=20	n=20	n=20	
GMT (95% CI) against Delta variant	NA	93.22	212.46	164.86	0.0012
		(65.18, 133.33)	(143.96, 313.54)	(121.38, 223.91)	
GMT (95% CI) against Omicron variant	NA	1.39	54.34	22.33	0.001
		(0.21, 9.10)	(17.76, 166.25)	(4.68, 106.44)	
ChAdOx1-prime (n=112)	BBIBP-CorV	ChAdOx1	30 µg BNT162b2	15 µg BNT162b2	*p*-value
	n=22	n=30	n=30	n=30	
PRNT$_{50}$ at 2 weeks after boosting					
GMT (95% CI) against Delta variant	49.0	69.1	470.1	358.4	<0.0001
	(37.56, 64.05)	(50.14, 95.14)	(395.49, 558.89)	(276.13, 465.26)	
GMR (95% CI) between post-boosting and post-primary series* against Delta variant	0.70	0.99	6.74	5.14	<0.0001
	(0.44, 1.12)	(0.60, 1.63)	(4.45, 10.23)	(3.24, 8.16)	
GMT (95% CI) against Beta variant	28.1	38.2	292.9	250.0	<0.0001
	(18.08, 43.53)	(26.06, 56.05)	(233.73, 367.17)	(182.95, 341.51)	
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	0.65	0.88	6.73	5.75	<0.0001
	(0.36, 1.15)	(0.52, 1.49)	(4.42, 10.26)	(3.57, 9.24)	
PVNT$_{50}$ at 2 weeks after boosting		n=20	n=20	n=20	
GMT (95% CI) against Delta variant		120.6	1,081.2	720.66	0.0001
		(77.63, 187.36)	(797.92, 1,465.1)	(505.26, 1,027.9)	
GMT (95% CI) against Omicron variant		3.25	521.16	232.31	0.0001
		(0.60, 17.53)	(396.91, 684.30)	(155.20, 347.72)	
PVNT$_{50}$ at 16-20 weeks after boosting			n=20	n=20	
GMT (95% CI) against Delta variant	NA	NA	207.1	178.63	0.0012
			(158.57, 270.47)	(120.49, 264.83)	

GMT (95% CI) against Omicron variant	NA	NA	116.88 (76.94, 177.54)	14.04 (3.138, 62.83)	0.001

* The geometric mean ratio (GMR) of PRNT50 between post-boosting and post-primary series. The post primary series GMC was derived from the study in the same setting as the current study []The post primary series GMT (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, were 21.2 (16.07, 27.87) and 10.2 (7.92, 13.12) against Delta and Beta variants, respectively; and after 2-dose homologous ChAdOx1,10 weeks apart, were 69.7 (48.08, 101.00) and 43.5 (30.73, 61.72) against Delta and Beta variants, respectively.

CI: confidence interval; IQR: interquartile range

Supplementary Table 1: Adverse events of following booster vaccination

Adverse events (AEs)	BBIBP-CorV	ChAdOx1	30 μg BNT162b2	15 μg BNT162b2	*p*-value
CoronaVac-prime (n=179)	**n=14**	**n=65**	**n=50**	**n=50**	
Overall AEs (%)	10 (71.43)	64 (98.46)	46 (92.0)	40 (80.0)	0.002
Injection site reaction (%)	9 (64.29)	62 (95.38)	46 (92.00)	36 (72.00)	<0.001
Fatigue (%)	2 (14.29)	46 (70.77)	26 (52.0)	10 (20.00)	<0.001
Headache (%)	1 (7.14)	12 (18.46)	25 (50.0)	18 (36.0)	<0.001
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	0	1 (1.54)	31 (62.0)	20 (40.0)	<0.001
Nausea (%)	2 (14.29)	20 (30.77)	7 (14.0)	5 (10.0)	0.119
Diarrhea (%)	1 (7.14)	12 (18.46)	3 (6.0)	6 (12.0)	0.284
Fever (%)	1 (7.14)	25 (38.46)	4 (8.0)	1 (2.0)	<0.001
Rash (%)	2 (14.29)	9 (13.85)	7 (14.0)	2 (4.0)	0.341
Somnolence (%)	0	0	2 (4.0)	2 (4.0)	0.357
Flu-like symptoms (%)	0	4 (6.15)	1 (2.0)	1 (2.0)	0.453
Arthralgia (%)	0	2 (3.08)	1 (2.0)	1 (2.0)	0.906
Dizziness (%)	0	1 (1.54)	1 (2.0)	0	0.758
Paresthesia (%)	2 (14.29)	1 (1.54)	1 (2.0)	0	0.014
Vomiting (%)	0	4 (6.15)	0	1 (2.0)	0.199
ChAdOx1-prime (n=173)	**n=23**	**n=50**	**n=50**	**n=50**	
Overall AEs (%)	14 (60.87)	36 (72.0)	49 (958.0)	44 (89.0)	<0.001
Injection site reaction (%)	9 (39.13)	28 (56.0)	47 (94.00)	44 (88.00)	<0.001
Fatigue (%)	3 (13.04)	18 (36.0)	34 (68.0)	20 (40.00)	<0.001
Headache (%)	6 (26.09)	15 (30.0)	28 (56.0)	28 (56.0)	0.024
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	7 (30.43)	21 (42.0)	34 (68.0)	37 (74)	0.001
Nausea (%)	1 (4.35)	20 (30.77)	7 (14.0)	5 (10.0)	0.102
Diarrhea (%)	1 (4.35)	5 (10.0)	8 (16.0)	6 (10.0)	0.834
Fever (%)	1 (4.35)	2 (4.0)	4 (8.0)	1 (2.0)	0.240
Rash (%)	0	1 (2.0)	1 (2.0)	0	0.688
Somnolence (%)	0	1 (2.0)	2 (4.0)	0	0.421
Flu like symptoms (%)	0	1 (2.0)	2 (4.0)	2 (4.0)	0.738
Arthralgia (%)	0	0	0	1 (2.0)	0.480
Dizziness (%)	2 (8.70)	1 (2.0)	0	0	0.118
Paresthesia (%)	0	0	0	0	-
Vomiting (%)	0	3 (6.0)	0	0	0.057

Supplementary Table 2: Anti-RBD IgG geometric mean concentration (GMC) and the geometric mean ratio (GMR) between post boosting and pre-boosting (baseline) or post primary series* and IGRA positive rate

Anti-RBD IgG geometric mean concentration (GMC), BAU/mL	Type of booster vaccinations				
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value between groups
GMC (95%CI) at baseline	34.32 (22.33, 52.77)	38.18 (31.21, 46.71)	33.31 (26.72, 41.53)	37.67 (31.65, 44.84)	0.7616
GMC (95%CI) post boosting	154.6 (92.11, 259.47)	1358.0 (1141.84, 1615.07)	5152.2 (4491.65, 5909.83)	3981.1 (3397.15, 4665.42)	<0.0001
GMR (95% CI) between post-boosting and baseline	4.5 (2.98, 6.80)	35.6 (29.18, 43.34)	154.7 (124.30, 192.50)	105.7 (90.31, 123.68)	<0.0001
GMR (95% CI) between post-boosting and post primary series of CoronaVac*	0.94 (0.53, 1.67)	8.26 (6.29, 10.85)	31.34 (24.37, 40.30)	24.22 (18.60, 31.54)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	5 (35.7)	12 (18.5)	16 (32)	12 (24)	0.301
Post-boosting IGRA positive among baseline negative participants, n (%)	1/9 (11.1)	26/53 (49.1)	28/34 (82.4)	30/38 (79.0)	<0.0001
ChAdOx1-prime (n=173)					
	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=49	15 µg BNT162b2 n=50	*p*-value between groups
GMC (95%CI) at baseline	106.6 (70.89, 160.29)	105.7 (80.97, 137.97)	95.98 (75.84, 121.45)	90.11 (73.62, 110.30)	0.7661
GMC (95%CI) post boosting	128.1 (93.52, 175.37)	246.4 (199.59, 304.20)	2363.8 (2005.58, 2786.06)	1961.9 (1624.61, 2369.10)	<0.0001
GMR (95% CI) between post-boosting and baseline	1.2 (1.01, 1.43)	2.3 (1.92, 2.83)	25.1 (20.30, 31.01)	21.8 (18.28, 25.92)	<0.0001
GMR (95% CI) between post-boosting and primary series of ChAdOx1*	0.46 (0.28, 0.65)	0.88 (0.58, 1.13)	8.49 (5.71, 10.44)	7.04 (4.69, 8.84)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	13 (56.5)	26 (52.0)	9 (18.0)	14 (28.0)	<0.0001
Post-boosting IGRA positive among baseline negative participants, n (%)	0/10 (0)	0/24 (0)	31/41 (75.6)	24/26 (66.7)	<0.0001

*The post primary series GMC was derived from the study in the same setting as the current study.[7] The post primary series GMC (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, was 164.4 (133.55, 202.43); and after 2-dose homologous ChAdOx1,10 weeks apart, was 278.5 (195.66,396.33).

CI: confidence interval; IQR: interquartile range

A

Ag-Nil (IU/mL)

B

Ag1-Nil (IU/mL)

CoronaVac primary series | ChAdOx1 primary series

C

Ag2-Nil (IU/mL)

CoronaVac primary series | ChAdOx1 primary series